Iodine-123 clinical trials
How each study uses Iodine-123 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 5 |
| 2007 | 6 |
| 2013 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 16
Institute for Neurodegenerative Disorders (12) · Molecular NeuroImaging (3) · GE Healthcare (2) · Tomsk National Research Medical Center of the Russian Academy of Sciences (1)
Studies
Open first, then newest update. How each study uses Iodine-123 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1CompletedPhase 1Tomsk National Research Medical Center of the Russian Academy of SciencesNCT06386653Written as Diagnostic injection of [123I]I-DARPIN-Ec1How we know
- A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsCompletedPhase 3GE HealthcareNCT04193527Written as DaTSCAN™ Ioflupane (123I) InjectionHow we know
- A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.CompletedPhase 1GE HealthcareNCT04564092Written as DaTSCAN™ Ioflupane (123I) InjectionHow we know
- A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseStatus unknownPhase 2Institute for Neurodegenerative DisordersNCT00387075Written as [123I]β-CITHow we know
- Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsCompletedPhase 1Institute for Neurodegenerative DisordersNCT00556660Written as [123I] AV-151How we know
- Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.CompletedPhase 1Molecular NeuroImagingNCT01859767Written as [123I]MNI-672 SPECTHow we know
- Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease ProgressionCompletedPhase 2Institute for Neurodegenerative DisordersNCT00134784Written as [123I]B-CIT SPECT imagingHow we know
- Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic UncertaintyCompletedPhase 2Institute for Neurodegenerative DisordersNCT00129675Written as [123I]ß CITHow we know
- Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00315250Written as [123I]β-CITHow we know
- Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk FamiliesCompletedPhase 2Institute for Neurodegenerative DisordersNCT00273351Written as [123I]B-CITHow we know
- Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00480701Written as [123I]-IBVMHow we know
- Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00397696Written as [123I] 5-IAHow we know
- A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00117819Written as [123I]ß CIT and SPECT imagingHow we know
- Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the BrainCompletedPhase 1Institute for Neurodegenerative DisordersNCT00287248Written as [123I] IMPY & SPECT ImagingHow we know
- Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsTerminatedPhase 1Institute for Neurodegenerative DisordersNCT00427674Written as [123I] mZINT injection and serial dynamic SPECT imagingHow we know
- Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsTerminatedPhase 1Institute for Neurodegenerative DisordersNCT00605059Written as [123I]AV94How we know
- Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HCTerminatedPhase 1Molecular NeuroImagingNCT00544453Written as [123I] MNI-308How we know
- Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy SubjectsCompletedPhase 1Molecular NeuroImagingNCT00439010Written as [123I] AV 39How we know
Codes
What other systems call Iodine-123 · ClinicalTrials.gg INT000618
- MeSH (NLM) C000614958Iodine-123One source NLM
- UNII (FDA) 8YWR746RPQIODINE I-123Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614958 | Iodine-123 | One source NLM |
| UNII (FDA) | 8YWR746RPQ | IODINE I-123 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.